Literature DB >> 17444586

Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.

David Launay1, Luc Mouthon, Eric Hachulla, Christian Pagnoux, Pascal de Groote, Martine Remy-Jardin, Regis Matran, Marc Lambert, Viviane Queyrel, Sandrine Morell-Dubois, Loic Guillevin, Pierre-Yves Hatron.   

Abstract

OBJECTIVE: To determine the prevalence and characteristics of moderate to severe pulmonary hypertension (PH) in patients with systemic sclerosis (SSc) with and without interstitial lung disease (ILD).
METHODS: We retrospectively studied clinical and functional characteristics of 197 consecutive patients with SSc who had undergone a screening echocardiography to detect PH.
RESULTS: Moderate to severe PH was suspected in 36 patients (18.3%) and confirmed in 32 who underwent right heart catheterization. The prevalence of PH did not differ between patients with limited and patients with diffuse cutaneous SSc. PH was detected in 12/67 (17.9%) patients without ILD vs 24/110 (21.8%) patients with ILD (p not significant). In patients with ILD, a lower PaO2 appeared as the unique independent factor significantly associated with PH, regardless of the extent of fibrosis. In 3 patients out of 9 (33.3%) with ILD and significantly restrictive disease, PH was out of proportion to the degree of fibrosis. In patients with no ILD, a higher grade of dyspnea appeared as the unique independent factor associated with PH. In patients with no ILD, altered DLCO was the sole indicator of the pulmonary function tests associated with PH (best cutoff value 72%). DLCO correlated with systolic pulmonary arterial pressure only in patients with no ILD.
CONCLUSION: Prevalence of moderate to severe PH was similar in SSc patients with and those without ILD. In patients with ILD, a lower PaO2 was the unique independent indicator associated with PH. In some patients with severe ILD, PH was out of proportion to the degree of fibrosis. A linear correlation between DLCO and systolic pulmonary arterial pressure was observed only in patients without ILD. All these indicators should assist identification of patients with or without ILD requiring diagnostic procedures for PH before annual screening.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17444586

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  25 in total

Review 1.  Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis.

Authors:  Aaliya Yaqub; Lorinda Chung
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

Review 2.  Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review.

Authors:  Heather Gladue; Nezam Altorok; Whitney Townsend; Vallerie McLaughlin; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2013-09-05       Impact factor: 5.532

3.  Associated pulmonary arterial hypertension in connective tissue diseases.

Authors:  Manole Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Buchar)       Date:  2011-04

4.  Multiparametric Magnetic Resonance Imaging in the Assessment of Pulmonary Hypertension: Initial Experience of a One-Stop Study.

Authors:  Gisela M B Meyer; Fernanda B Spilimbergo; Stephan Altmayer; Gabriel S Pacini; Matheus Zanon; Guilherme Watte; Edson Marchiori; Bruno Hochhegger
Journal:  Lung       Date:  2018-02-12       Impact factor: 2.584

5.  Pulmonary hypertension in patients with interstitial pneumonia with autoimmune features.

Authors:  Bashar N Alzghoul; Robert Hamburger; Thomas Lewandowski; Brandon Janssen; Daniel Grey; Wei Xue; Ali Ataya; Hassan Alnuaimat; Diana C Gomez-Manjarres; Divya Patel; Raju Reddy
Journal:  Pulm Circ       Date:  2020-12-07       Impact factor: 3.017

6.  Clinical and laboratory profiles of 136 systemic sclerosis patients with and without echocardiographically detected pulmonary hypertension.

Authors:  J-H Tao; Y-N Wan; Y Zhang; J-W Yan; Y-J Wang; G-J Yang; X-P Li; D-Q Ye; J Wang
Journal:  Z Rheumatol       Date:  2015-02       Impact factor: 1.372

Review 7.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

Review 8.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

9.  Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury.

Authors:  Sarah A Pendergrass; Everett Hayes; Giuseppina Farina; Raphael Lemaire; Harrison W Farber; Michael L Whitfield; Robert Lafyatis
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

Review 10.  Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis.

Authors:  Anupama Shahane
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.